板塊異動 | 生物醫藥股逆市上漲,君實生物漲超10%
uSMART友信智投10月8日消息,生物醫藥板塊今日逆市上揚。
回港二次上市的中概股再鼎醫藥-SB盤中漲超7%,在港上市7個交易日,累計漲幅超過26%。麥格理髮表研究報告,首次給予再鼎醫藥-SB“跑贏大市”評級,目標價810.16港元。該行指出,再鼎醫藥擁有2款已上市產品、3款待批及3款進入關鍵試驗期,公司自2015年起每年都會新增2至3個新項目,內部研發能力具優勢,認爲其平臺潛在價值被低估。
君實生物盤中漲超10%,公司公告稱研究中新藥對新冠肺炎患者有良好療效。對BLAZE-1研究所進行的一項新期中分析數據顯示,LY-CoV555及JS016的聯合療法在降低病毒載量、減輕症狀及降低和冠狀病毒相關的住院及急診治療方面均顯示出良好療效。基於聯合療法數據以及先前披露的治療的試驗結果,公司的合作夥伴禮來製藥已與全球監管機構(包括FDA)就單藥療法緊急使用授權的可能性進行接洽。在取得額外的安全性數據及充足的生產供應後,禮來製藥預計將於2020年11月提交聯合療法的EUA申請。禮來製藥預期最早於2021年第2季度取得數據並提交聯合療法的生物製品許可申請。
復宏漢霖-B盤中漲超8%,其正在開發的一款新冠病毒中和抗體HLX70針對新冠肺炎、新冠病毒引起的急性呼吸窘迫綜合徵(ARDS)或多重器官衰竭等適應症的新藥臨牀試驗申請(IND)獲得美國FDA的批準。公司因此成爲首個自主向美國FDA遞交新冠病毒中和抗體臨牀試驗申請並獲得批準的中國製藥企業。
此外,次新股嘉和生物-B盤中漲超3%,啓明醫療-B、康希諾生物-B、歐康維視生物-B等均有不同程度漲幅。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.